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Background. Despite sparse efﬁcacy data, tenofovir–emtricitabine or tenofovir–lamivudine plus nevirapine is used in many
resource-constrained settings.
Methods. This retrospective cohort study included patients initiating nevirapine-based antiretroviral therapy (ART) with either
tenofovir–emtricitabine or lamivudine (tenofovir group) or zidovudine–lamivudine (zidovudine group). Clinical, virologic, and im-
munologic evaluations were performed at baseline and every 6 months. Virologic failure was deﬁned as 2 consecutive human im-
munodeﬁciency virus (HIV)-RNAvalues >1000 copies/mL. Patients were included from ART initiation until time of failure, regimen
switch, discontinuation, or last HIV-RNA measurement. Cox proportional hazards regression was used to model factors inﬂuencing
time to failure. Bias due to dependent censoring was investigated via inverse probability weighted pooled logistic regression.
Results. A total of 5547 patients were evaluated; 1484 (26.8%) were in the tenofovir group and 4063 (73.2%) were in the zido-
vudine group. In the adjusted model, tenofovir regimen (hazard ratio [HR], 1.47; 95% conﬁdence interval [CI], 1.21–1.79) and higher
baseline log10 HIV-RNA (HR, 1.15; 95% CI, 1.03–1.28) were associated with virologic failure. Higher baseline log10 CD4+ cell count
(HR, 0.50; 95% CI, .40–.63) and increasing age (HR, 0.98; 95% CI, .97–.99) decreased the risk of virologic failure. Inverse probability
weighting results were consistent with the primary analysis.
Conclusions. Comparedwithzidovudine–lamivudine, theuseof tenofovir–lamivudineoremtricitabine incombinationwithnevirapine
was a strong predictor of virologic failure in our cohort, which was not explained by other risk factors or criteria for regimen selection.
Keywords. zidovudine; tenofovir; nevirapine; virologic failure; antiretroviral therapy.
Based on relative safety, efﬁcacy, and convenience, the World
Health Organization (WHO) recommends efavirenz, tenofovir,
plus either emtricitabine or lamivudine as the sole, preferred
ﬁrst-line antiretroviral therapy (ART) regimen for human
immunodeﬁciency virus (HIV)–infected adults living in re-
source-constrained settings [1]. When efavirenz cannot be
used, nevirapine remains the alternate nonnucleoside reverse
transcriptase inhibitor (NNRTI) option, given with the follow-
ing 2 nucleoside reverse transcriptase inhibitors (NRTIs): zido-
vudine plus lamivudine or tenofovir plus either emtricitabine or
lamivudine [1]. When combined with efavirenz, tenofovir is
superior to zidovudine. Speciﬁcally, higher rates of virologic
suppression were reported among patients on efavirenz-based
ART who received tenofovir–emtricitabine vs zidovudine–
lamivudine (81% vs 70%; P = .005) in addition to lower rates of
ART discontinuation due to adverse events (4% vs 9%, respec-
tively, P = .02) [2].
In clinical practice, the strength of tenofovir was extrapolated
from these data to nevirapine-based regimens, despite the lack
of associated outcome data. Simultaneously, there was a global
focus on increasing access to tenofovir to avoid zidovudine-
related toxicities. Consistent with WHO guidelines in 2008, ap-
proximately 20% of patients on ﬁrst-line ART in our clinical
program were receiving a tenofovir plus nevirapine-containing
regimen; only nevirapine plus zidovudine and lamivudine was
more commonly used. Since then, the efﬁcacy of ART containing
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tenofovir and nevirapine has been questioned by results from
small prospective [3–6] and larger retrospective studies [7–
10], suggesting that higher rates of virologic failure or worse clin-
ical outcomes occur with nevirapine plus tenofovir vs comparator
regimens. Existing data are limited by the use of more potent
comparator groups, small sample size, cross-sectional study de-
sign, or lack of virologic outcomes.
To address this gap, data from a large observational clinical
cohort were used to conduct a robust comparison of virologic out-
comes among HIV-infected patients on ﬁrst-line, nevirapine-
based ART. This study addresses the important question of
which commonly used NRTI combination (zidovudine- vs teno-
fovir-containing) performs best with nevirapine; this is a question
of great clinical signiﬁcance for patients unable to take efavirenz.
Accordingly, the primary objective was to evaluate the inﬂuence of
the NRTI combination on time to virologic failure in our cohort.
METHODS
In this retrospective cohort study, prospectively collected data
from a large clinical cohort in Nigeria were used. Between June
2004 and February 2012, the Harvard T. H. Chan School of Pub-
lic Health (Harvard) collaborated with the AIDS Prevention Ini-
tiative in Nigeria Ltd./Gte. (APIN) to support HIV prevention,
care, and treatment to over 160 000 patients, funded by the Pres-
ident’s Emergency Plan for AIDS Relief (PEPFAR). Upon pro-
gram entry, patients underwent a clinical examination and
baseline laboratory testing including hematology and chemistry,
CD4+ cell count (Cyﬂow, Partec), HIV-RNA (Cobas Amplicor
Monitor Assay, Roche Diagnostics), hepatitis B virus (HBV) sur-
face antigen (Monolisa HBsAg Ultra3, BioRad), and hepatitis C
virus (HCV) antibody (DIA.PRO Diagnostic, Bioprobes srl) as-
sessments. Patients eligible for ART, based on guidelines at the
time of program entry, initiated standard ﬁrst-line ART with 1
NNRTI and 2 NRTIs [11, 12]. Prescription reﬁlls were obtained
monthly; clinical visits and laboratory tests were performed every
6 months, or earlier if necessary. All patient data were maintained
in previously described electronic databases [13].
Ethical Considerations
All patients in the Harvard–APIN program provided written
consent for care. Only those who consented to the use of
their information for research were included in this analysis. In-
stitutional review boards at Harvard and the individual clinics
(Jos University Teaching Hospital, Nigerian Institute of Medical
Research, 68 Military Hospital, and University of Maiduguri
Teaching Hospital) approved the treatment protocol and data
collection forms. Because we used de-identiﬁed data, the
study was veriﬁed exempt from human subject review by insti-
tutional review boards.
Patient Selection
Antiretroviral-naive, HIV-1–infected adults (aged ≥18 years) who
initiated nevirapine-based ART with zidovudine–lamivudine
(zidovudine group) or nevirapine-based ART with tenofovir–
emtricitabine or tenofovir–lamivudine (tenofovir group) from
2006 to 2008 were included. Patients with prior antiretroviral
experience, missing baseline HIV-RNA or CD4+ cell count
data, no follow-up HIV-RNA after at least 6 months on treatment,
no ART reﬁlls, or inconsistent ART regimens over 6 months
(ie, regimen changed with each reﬁll) were excluded. Patient
data were included from time of ART initiation (baseline) through
18 months post-ART initiation.
Patients in the zidovudine group received zidovudine 300
mg, lamivudine 150 mg, and nevirapine 200 mg twice daily as
a ﬁxed dose combination (FDC) tablet (Aspen Pharmacare or
Aurobindo Pharma Limited). Patients in the tenofovir group re-
ceived nevirapine (Aurobindo) 200 mg twice daily with a once-
daily FDC tablet of tenofovir–emtricitabine 300 mg–200 mg
(Truvada, Aspen Pharmacare) or tenofovir–lamivudine 300
mg–300 mg (Matrix Laboratories Limited); use of the emtrici-
tabine- or lamivudine-containing product was based on avail-
ability during the study period.
Study Deﬁnitions
Sex, age, HBV or HCV coinfection, and WHO HIV clinical
stage were evaluated at baseline. Tuberculosis coinfection and
ART adherence were evaluated throughout the observation pe-
riod. Adherence was estimated using ART reﬁll data from base-
line through the study-deﬁned event or censoring [14, 15]. The
average adherence rate was calculated as the proportion of time
the patient had pills available (number of days supplied/number
of days between reﬁlls) and was truncated at 100%. A prespec-
iﬁed adherence cutoff of 95% was used for categorical assess-
ment of adherence.
Study events were conﬁrmed virologic failure, ART switch,
discontinuation, and unconﬁrmed virologic failure. Conﬁrmed
virologic failure was the primary outcome variable. In accor-
dance with the clinical protocol, conﬁrmed virologic failure
was deﬁned as 2 consecutive HIV-RNA >1000 copies/mL
after 6 months on ART or switch to a second-line ART regimen,
deﬁned as protease inhibitor–based ART following an HIV-
RNA >400 copies/mL. Time to virologic failure was the time
from ART initiation to the ﬁrst HIV-RNA >1000 copies/mL
or the ﬁrst protease inhibitor-based prescription. ART switch
was deﬁned as a change in ART for reasons other than virologic
failure, with the exception of a switch between emtricitabine
and lamivudine. The ART switch date was the date on which
the new ART regimen was ﬁrst dispensed. Discontinuation was
deﬁned as death, lost to follow-up (no ART reﬁll for 6 months),
or transferred or withdrew from the program. Time to discon-
tinuation was calculated using the last recorded ART dispense
date. Unconﬁrmed virologic failure was included to evaluate the
potential inﬂuence of requiring 2 HIV-RNA results as our pri-
mary endpoint and was deﬁned as HIV-RNA >1000 copies/mL
without a consecutive conﬁrmatory HIV-RNA measurement.
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Time to unconﬁrmed virologic failure was calculated using the
date when the HIV-RNA measurement was >1000 copies/mL.
Follow-up time was censored at the ﬁrst event, and subsequent
events were not included. For patients who did not experience a
study event, follow-up was censored at last HIV-RNAwithin the
study period.
Statistical Analyses
Subject demographics were compared between groups using the
Wilcoxon rank sum test for continuous variables or the χ2 test
of independence for categorical variables.
Time to Virologic Failure Regression Modeling
Bivariate analyses were used to evaluate variables for inclusion
in the Cox proportional hazards model; categorical variables
were evaluated using the log-rank test, and continuous variables
were evaluated using Cox proportional hazards regression [16].
Variables with a bivariate P < .25 and clinically relevant variables
(adherence, age, serum creatinine) were considered candidates
for inclusion in the initial Cox model. Kaplan–Meier graphs
were generated for categorical variables to reveal violations of
the Cox model’s assumption of proportionality.
A Cox proportional hazards model was ﬁtted by means of
manual backward elimination of single covariates based on
the likelihood ratio test and the comparison of hazard ratios be-
tween the model with and without the covariate in question. All
statistically signiﬁcant covariates, clinically relevant covariates
(signiﬁcant or not), effect modiﬁers, and confounders were re-
tained in the ﬁnal model. The scale of continuous covariates was
evaluated using the design variable method. All interactions
were examined using the likelihood ratio test. The proportion-
ality assumption was assessed for covariates using Schoenfeld
residuals, and the overall ﬁt of the model was evaluated using
Cox–Snell residuals.
Evaluation of Dependent Censoring
The possibility of bias due to dependent censoring was evaluat-
ed by ﬁtting a time-updated Cox regression model to assess the
association between time-varying factors for each study-deﬁned
event [17]. Because clinical visits occur at 6-month intervals,
laboratory values were carried forward up to 7 months to ac-
commodate late visits. Percent adherence values were carried
backward because adherence is calculated at the end of a pre-
scription reﬁll cycle. An inverse probability weighting (IPW)
Figure 1. Flow diagram of eligible patients included in the cohort analysis in the final Cox proportional hazards model. Abbreviations: ART, antiretroviral therapy; HBV,
hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; LTFU, lost to follow-up.
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analysis was performed to assess potential bias due to depen-
dent censoring by competing outcomes by ﬁtting an IPW
pooled logistic regression model using only uncensored per-
son-time observations for the outcome of interest [18].
RESULTS
During the study period, 6575 patients were identiﬁed for inclu-
sion and 5547 (84%) had data available for all variables in the
ﬁnal model—4063 (73.2%) in the zidovudine group and 1484
(26.8%) in the tenofovir group (Figure 1). The most common
reason for exclusion was missing HBV or HCV status
(11.0%). Baseline participant characteristics are summarized
in Table 1. Consistent with clinical considerations for selecting
an NRTI, HBV coinfection was more common among those in
the tenofovir vs zidovudine group (27.2% vs 14.9%; P < .001), as
was a lower median baseline hemoglobin (100 vs 110 g/L,
P < .001). Proportionally, more women, patients with HCV co-
infection, and those with more advanced HIV disease received
tenofovir. Median (interquartile range [IQR]) duration of time
to event or censor was slightly longer for the zidovudine group
compared with the tenofovir group (392 [244] vs 376 [170]
days, P < .001).
Among patients in the tenofovir group, 1043 (70.2%) received
emtricitabine as their second NRTI, 190 (12.8%) received lami-
vudine, and 252 (19.8%) switched between emtricitabine and
lamivudine during the study period (median [IQR] time to
switch was 172 [97] days). The number of virologic failure events
did not differ signiﬁcantly between patients receiving emtricita-
bine or lamivudine (P = .47); therefore, data were combined in
the ﬁnal analysis irrespective of emtricitabine or lamivudine use.
Overall, the median ART adherence rate was 95.3%, which
was similar between the zidovudine and tenofovir groups
(95.2% vs 95.8%). Among those who experienced virologic fail-
ure, more patients had adherence <95% compared with ≥95%
(56.4% vs 43.6%; P < .001), but there was no difference in me-
dian adherence between those patients with failure in the zido-
vudine or tenofovir groups (91.9% vs 93.6%; P = .36).
Patients in the tenofovir group had a higher rate of virologic
failure and discontinuation (Table 1). Figure 2 represents time
to virologic failure between the groups. Of the 957 patients with
a discontinuation event, 14 (1.5%) died, 849 (88.7%) were lost to
follow-up, 92 (9.6%) transferred to another site, and 2 (0.2%)
withdrew from the program. These distributions were similar
between NRTI groups (P = .50).
Time to Virologic Failure
After adjusting for other baseline risk factors, patients in the
tenofovir group had higher risk of virologic failure (adjusted
hazard ratio [aHR], 1.47; 95% conﬁdence interval [CI],
1.21–1.79; Table 2). Consistent with indicators of disease
progression, the risk of virologic failure decreased with a high-
er baseline CD4+ cell count (aHR, 0.50; 95% CI, .40–.63),
while a higher baseline HIV-RNA increased the risk of failure
(aHR, 1.15; 95% CI, 1.03–1.28). Adherence was omitted from
the ﬁnal Cox model because it may have been on the causal
pathway (ie, adherence is a potential mediator of the effect
of regimen assignment) [19, 20]. Given its clinical importance,
the Cox model that includes adherence is presented in Supple-
mentary Table 1. While adherence <95% increased the risk of
virologic failure (aHR, 1.28; 95% CI, 1.07–1.54), the inclusion
of adherence in the Cox model had no notable effect on the
HR or CI of the remaining covariates (tenofovir group aHR,
1.48; 95% CI, 1.21–1.80).
When the Cox analysis was restricted to virologic failures that
occurred beyond 12 months, the regimen was no longer associ-
ated with virologic failure (aHR, 1.99; 95% CI, .94–4.21). How-
ever, the number of participants and the number of events that
occurred during the 12–18 months were small (n = 3120 partic-
ipants with 37 virologic failure events).
Evaluation of Other Outcome Differences or Dependent Censoring
Additional outcome-speciﬁc, time-updated Cox models were
constructed for each of our deﬁned outcomes to evaluate the ef-
fect of regimen on events outside of virologic failure (Supple-
mentary Table 2). Discontinuation and unconﬁrmed virologic
failure outcomes were not associated with treatment regimen.
ART switch was associated with treatment regimen, indicating
that patients in the tenofovir group were 34% more likely to
switch regimens (aHR, 1.34; 95% CI, 1.15–1.57). The effect of
regimen on time to virologic failure was consistent between
the primary and time-updated models and reﬂected a 47%
increase in the risk of virologic failure for patients in the teno-
fovir group (aHR, 1.47; 95% CI, 1.24–1.75). While these models
did not rule out dependent censoring, we found an overall
agreement between IPW analysis results (Table 2) and the pri-
mary Cox proportional hazards results related to the impact of
the study group on virologic failure, demonstrating that depen-
dent censoring did not compromise the original nontime-
updated Cox model estimates.
DISCUSSION
The Harvard–APIN program initially identiﬁed a high rate of
conﬁrmed virologic failure among patients on nevirapine plus
tenofovir and emtricitabine or lamivudine compared with
other WHO-recommended or alternative ﬁrst-line regimens
[7]. To evaluate the speciﬁc impact of the NRTI combination
with nevirapine, we focused on patients initiating nevirapine-
based ART combined with either zidovudine or tenofovir
using Cox proportional hazards, time varying analysis, and
IPW modeling. These results indicate that among patients ini-
tiating nevirapine, the use of tenofovir carried a 47% greater risk
of virologic failure compared with the use of zidovudine; this
difference persisted after adjusting for other variables that
may inﬂuence regimen selection and treatment outcomes
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(Table 2). Tenofovir beneﬁts were not observed in other out-
comes; speciﬁcally, the tenofovir group had higher risk for reg-
imen switch and similar risk for discontinuation. Notably, we
did not observe signiﬁcantly higher virologic failure in the teno-
fovir group after 12 months of ART, suggesting that patients
already virologically suppressed on nevirapine plus tenofovir
may not be at increased risk for virologic failure. These data
have signiﬁcant clinical implications for adults living in low-
and middle-income countries who require an alternative to efa-
virenz for ﬁrst-line ART [1].
Our results are consistent with those from other evaluations
of outcomes among patients who received ART containing ne-
virapine and tenofovir, thus supporting the belief that NNRTI
effectiveness differs by NRTI selection. The DAUFIN study,
which evaluated the effectiveness and tolerability of nevira-
pine given either with zidovudine–lamivudine or tenofovir–
lamivudine in antiretroviral-naive patients, was terminated
early due to high rates of early virologic failure in the tenofovir
arm [6]; 9 of 36 patients receiving tenofovir experienced virolog-
ic failure, 8 during the ﬁrst 12 weeks of the study, compared
with only 1 of 35 patients receiving zidovudine. Lapadula et al
also reported early virologic failure in patients receiving tenofo-
vir–emtricitabine plus nevirapine compared with ritonavir-
boosted atazanavir [5]. In another pilot study that described
virologic outcomes among 23 patients receiving once-daily ne-
virapine plus tenofovir–lamivudine, only 10 patients achieved
HIV-RNA <75 copies/mL by week 24 [3]. Turning to large clin-
ical cohorts that evaluated this question, among 10 256 antire-
troviral-naive patients initiating either zidovudine or tenofovir
in combination with nevirapine in Zambia, 90-day mortality
was higher among patients who received tenofovir (aHR, 1.45;
95% CI, 1.03–2.06); however, this difference did not remain
Table 1. Baseline Characteristics and Outcomes of Study Participants
Tenofovir Group n = 1484 Zidovudine Group n = 4063 P Value
Baseline Characteristics
Age (y) 33 (11) 32 (11) .41
Female gender 1255 (84.6) 3085 (75.9) <.001
Hepatitis B virus coinfection 404 (27.2) 604 (14.9) <.001
Hepatitis C virus coinfection 144 (9.7) 294 (7.2) .003
CD4 count (cells/mm3) 122 (122) 143 (115) <.001
Human immunodeficiency virus-RNA (log10 copies/mL) 4.86 (1.1) 4.70 (1.2) <.001
World Health Organization Stage n = 1335 n = 3489 <.001
1 236 (17.7) 923 (26.5)
2 435 (32.6) 1042 (29.9)
3 494 (37.0) 1045 (30.0)
4 170 (12.7) 479 (13.7)
Tuberculosis coinfection 294 (19.8) 466 (11.5) <.001
Alanine transaminase (µkat/L) 0.42 (0.37) 0.40 (0.36) .04
Hemoglobin (g/L) 100 (24), n = 1462 110 (20), n = 3948 <.001
Creatinine (μmol/L) 77 (31), n = 1458 77 (31), n = 3880 .943
Study Outcomes
Virologic failure 159 (10.7) 298 (7.3) <.001
Antiretroviral therapy switch 256 (17.3) 622 (15.3) .079
Discontinue 308 (20.8) 649 (16.0) <.001
No event 761 (51.3) 2494 (61.4) <.001
Values shown as either median (interquartile range) or n (%); percent is based on the total n (or category n) of the regimen group, as appropriate. The Wilcoxon rank sum test was used for
continuous variables and the χ2 test of independence was used for categorical variables.
Figure 2. Kaplan–Meier graph of the time to confirmed virologic failure, defined
as the time of the first human immunodeficiency virus-RNA >1000 copies/mL, for
the tenofovir (TDF) and zidovudine (AZT) groups. Time is represented as days after
initiating nevirapine (NVP)-containing first-line antiretroviral therapy. Abbreviations:
3TC, lamivudine; FTC, emtricitabine.
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after sensitivity analyses, including time-varying analysis [9]. In
adjusted models from a large cohort study from southern Afri-
ca, patients on nevirapine plus tenofovir–emtricitabine
or tenofovir–lamivudine experienced signiﬁcantly higher rates
of mortality but lower rates of loss to follow-up when com-
pared with patients taking efavirenz plus similar NRTIs [21].
Consistent with these data, a metaanalysis of 33 studies com-
paring virologic efﬁcacy among the WHO-recommended
tenofovir-containing ﬁrst-line ART regimens highlighted poor-
er outcomes with the nevirapine plus tenofovir-containing
regimens [22].
The reason for the poorer performance of nevirapine–
tenofovir ART is unclear. One proposed mechanism is an intra-
cellular drug–drug interaction observed in vitro between tenofovir
and nevirapine, resulting in lower intracellular concentrations of
both antiretrovirals [23]. Differences in lamivudine vs emtricita-
bine pharmacokinetics have also been proposed. An observation-
al Dutch cohort study identiﬁed a higher risk of virologic failure
when lamivudine vs emtricitabine was combined with tenofovir
and either nevirapine (aHR 2.01; 95% CI, 1.36–2.98) or efavirenz
(aHR, 2.35; 95%CI, 1.61–3.42) [24]. Notably, our data did not
identify a difference in outcomes among patients in the tenofovir
group who received lamivudine or emtricitabine. Our results are
consistent with those from a metaanalysis of 12 randomized con-
trolled trials that compared 4913 patients randomized to lamivu-
dine or emtricitabine in addition to various ART combinations
and found that the 2 agents are clinically interchangeable [25].
Our ﬁndings are limited by the study’s retrospective cohort
design. At the time of data collection, WHO guidelines recom-
mended the use of either nevirapine or efavirenz in combina-
tion with zidovudine and lamivudine or with tenofovir and
emtricitabine or lamivudine for ﬁrst-line ART [11]. Regimen
selection may have been inﬂuenced by factors that we were
unable to measure or control for in our analysis, indicated by
differences in baseline characteristics (Table 1). To account
for some potential biases from dependent censoring, we gener-
ated an IPW pooled logistic regression model, and the close cor-
respondence between these models testiﬁes to the robustness of
the Cox estimates. Additionally, there may be limitations to
measuring adherence based on prescription reﬁll data, particu-
larly as it relates to pill burden. Although all patients received
nevirapine twice daily, there was a difference between groups
in the total number of pills per day. The zidovudine group re-
ceived nevirapine plus a twice-daily FDC tablet of zidovudine–
lamivudine (4 pills daily) or, beginning early 2007, a twice-daily
full regimen FDC tablet (2 pills daily). The tenofovir group
received nevirapine plus a once-daily FDC tablet of tenofovir–
emtricitabine or tenofovir–lamivudine (3 pills daily). For
twice-daily regimens, higher pill burden has previously been
associated with lower rates of both adherence and virologic
suppression (Spearman correlation, −0.67 and −0.75, respec-
tively; both P < .01) [26]. However, a difference in adherence
was not identiﬁed between our study groups and did not inﬂu-
ence the associated risk of virologic failure related to regimen
selection.
In conclusion, ART that includes tenofovir and nevirapine
should be initiated with caution. The WHO recommends nevi-
rapine as the alternative for patients who cannot take efavirenz,
and nevirapine remains widely used for ﬁrst-line ART in low-
and middle-income countries [1, 27]. These results offer impor-
tant information to guide selection of the NRTI combination
when designing an HIV treatment regimen, indicating a prefer-
ence for zidovudine over tenofovir when combined with nevira-
pine. These ﬁndings support the need for systematic evaluations
Table 2. Risk Estimates and 95% Confidence Intervals for Virologic Failure During 18 Months of First Line Antiretroviral Therapy
Factor
Cox Proportional Hazards Model
(n = 5547 Patients)
Inverse Probability Weighted Pooled Logistic
Regression (5697 Patients, 81 642 Observations)
HR 95% CI P Value OR 95% CI P Value
Tenofovir group 1.47 1.21, 1.79 .001 1.57 1.28, 1.94 .0001
Age 0.98 .97, .99 .002 0.99 .98, 1.00 .122
Female gender 0.91 .71, 1.17 .474 0.88 .69, 1.13 .309
Hepatitis B virus coinfection 0.96 .75, 1.23 .717 0.98 .78, 1.23 .862
Hepatitis C virus coinfection 1.17 .85, 1.61 .326 0.91 .66, 1.26 .554
CD4 count (log10) 0.50 .40, .63 <.001 0.997 .995, .998 <.0001
Human immunodeficiency virus-RNA (log10) 1.15 1.03, 1.28 .011 1.20 1.01, 1.32 .018
Tuberculosis coinfection . . . . . . . . . 0.72 .50, 1.05 .085
Alanine transaminase (µkat/L) . . . . . . . . . 1.11 1.00, 1.22 .052
Hemoglobin (g/L) . . . . . . . . . 1.00 .99, 1.00 .415
Creatinine (μmol/L) . . . . . . . . . 0.997 .993, .999 .013
All risk factors were measured at baseline.
Bold results indicate statistically significant results (P value <.05).
Abbreviations: CI, confidence interval; HR, hazard ratio; OR, odds ratio.
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of ART combinations before their inclusion in ART guidelines
and subsequent widespread implementation.
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